effect overlay
activetrials
Dementia
Dementia
TARGET TAU

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

HREC: 2024.121
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia
Dementia
TRAILBLAZER 5

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease: I5T-MC-AACO

HREC: 2024.122
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia
Dementia
SLT for Vascular Dementia

A Multicentre, Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effectiveness and Safety of Sailuotong (SLT), a Standardised Herbal Medicine Formula in Patients with Vascular Dementia and Alzheimer's Disease with Cerebrovascular Disease
 

HREC: 2018.225
Principal Investigator: A/Prof Nawaf Yassi
Coordinator contact: Sophie Robinson
Funding: Non-Commercial
Dementia
Dementia
SELENATE 002

A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probably Behavioural Variant Fronto-temporal Dementia
 

HREC: 2020.171
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Lauren Martell
Funding: Non-Commercial
Dementia
Dementia
EP004 - Anavex OLE

Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
 

HREC: 2020.257
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial